Benefits and costs of using HPV testing to screen for cervical cancer

JAMA

Volumn 287, Issue 18, 2002, Pages 2372-2381

  Mandelblatt, Jeanne S ^a   Lawrence, William F ^a   Womack, Sharita Mizell ^b,c   Jacobson, Denise ^d   Yi, Bin ^a   Hwang, Yi Ting ^a   Gold, Karen ^e,g   Barter, James ^a   Shah, Keerti ^f  

^a GEORGETOWN UNIVERSITY   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g ABT ASSOCIATES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HEALTH CARE COST; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RELIABILITY; UNITED STATES; UTERINE CERVIX CARCINOMA; VIRUS DIAGNOSIS; WART VIRUS;

EID: 0037042282     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.287.18.2372     Document Type: Article

References (135)

1. Diagnosing human papillomaviruses: Recent advances
2. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities
3. Meta-analysis of Pap test accuracy
4. A clinical trial of the autopap 300 QC system for quality control cervicovaginal cytology in the clinical laboratory
5. Computer-assisted cervical cancer screening using neural networks
6. Identifying women with cervical neoplasia using HPV DNA testing for equivocal pap test results
7. Comparison of ThinPrep preparations with conventional cervicovaginal smears
8. A new look at cervical cytology
9. Cost-effectiveness of 3 methods to enchance the sensitivity of Papanicolaou testing
10. Cost-effectiveness of rescreening conventionally prepared cervical smears by PAPNET testing
11. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia
12. Prevalence of human papillomavirus in cervical cancer
13. Human papillomavirus testing by Hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance
14. Human papillomavirus screening for women with atypical Papanicolaou smears
15. Atypical squamous cells: A case-series study of the association between Papanicolaou smear results and human papillomavirus DNA genotype
16. Toward objective quality assurance in cervical cytopathology
17. Detection of human papillomavirus in cervical scrapes by the polymerase chain reaction in relation to cytology
18. Variability of human papillomavirus DNA testing in a longitudinal cohort of young women
19. Should cervical cytologic testing be augmented by cervicography or human papillomavirus deoxyribonucleic acid detection?
20. Human papillomavirus in false negative archival cervical smears
21. HPV DNA testing in cervical cancer screening
22. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer
23. A systematic review of the role of human papillomavirus testing within a cervical screening programme
24. Comparison of PCR- and Hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies
25. Probabilistic sensitivity analysis using Monte Carlo simulation
26. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women
27. Is HIV infection a co-factor for cervical squamous cell neoplasia?
28. Human papillomavirus-associated cancer in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome
29. Natural history of cervical neoplasia
30. Epidemiology of genital human papillomavirus infection
31. Human papillomavirus investigation of patients with cervical intraepithelial neoplasia 3, some of whom progressed to invasive cancer
32. Interobserver reproducibility of cervical cytologic and histologic interpretations: Realistic estimates from the ASCUS-LSIL triage study
33. The Markov process in medical prognosis
34. Assessing the effectiveness of health interventions for cost-effectiveness analysis
35. Comparative analysis of human papillomavirus detection by Hybrid capture assay and routine cytologic screening to detect high-grade cervical lesions
36. Determinants of genital human papillomavirus infection in low-income women in Washington, DC
37. Human papillomavirus and invasive cervical cancer in Brazil
38. Design and methods of a population-based natural history study of cervical neoplasia in rural province of Costa Rica
39. Determinants of genital human papillomavirus infection in young women
40. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors
41. The frequency of human papillomavirus detection in postmenopausal women on hormone replacement therapy
42. Short-term fluctuations in the detection of cervical human papillomavirus DNA
43. Determinants of genital human papillomavirus infection among cytologically normal women attending the University of New Mexico student health center
44. Screening for cervical intraepithelial neoplasia grade 2/3: Validity of cytologic study, cervicography, and human papillomavirus detection
45. Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon
46. Human papillomavirus testing in primary cervical screening
47. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent
48. Risk factors for HPV detection in archival Pap smears
49. Papillomavirus detection: Demographic and behavioral characteristics influencing the identification of cervical disease
50. HPV testing in primary screening of older women
51. Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by Hybrid Capture II and polymerase chain reaction
52. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening
53. Determinants of persistent detection of human papillomavirus DNA in the uterine cervix
54. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities
55. Persistence of type-specific human papillomavirus infection among cytologically normal women
56. Evaluating cervical cancer screening programmes for developing countries
57. Behavior of mild cervical dysplasia during long-term follow-up
58. Natural history of dysplasia of the uterine cervix
59. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women
60. Human papillomavirus DNA and genotypes: Prognostic factors for progression of cervical intraepithelial neoplasia
61. Human papillomavirus types and cervical squamous intraepithelial lesions that recur after cold-knife conization
62. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection
63. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions
64. The presence of persistent high-risk HPV genotype in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months
65. Epidemiological evidence for age-dependent regression of preinvasive cervical cancer
66. Prospective follow-up of genital HPV infections: Survival analysis of the HPV typing data
67. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears
68. Natural history of cervical human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda System
69. An evaluation of screening policies for cervical cancer in England and Wales using a computer simulation model
70. Screening for cervical cancer
71. Prevalence of high risk genital papillomaviruses in the Belgian female population determined by fast multiplex polymerase chain reaction
72. Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing
73. HPV testing in primary screening of older women
74. Combined Pap smear, cervicography and HPV DNA testing in the detection of cervical intraepithelial neoplasia and cancer
75. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy
76. Prevalence of human papillomavirus in cervical scrapes as analyzed by PCR, in a population-based sample of women with and without cervical dysplasia
77. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix
78. Trends in self-reported use of mammograms (1989-1997) and Papanicolaou tests (1991-1997): Behavioral Risk Factor Surveillance System
79. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma
80. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer
81. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer
82. Toward consistency in cost-utility analyses
83. Determining costs of health care services for cost-effectiveness analyses
84. Costs and benefits of cervical screening, I: The costs of the cervical screening programme
85. Diagnostic and treatment procedures induced by cervical cancer screening
86. Patterns of care for invasive cervical cancer
87. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis
88. Observations on a model of the biology of carcinoma of the cervix
89. A cohort study of cervical cancer screening in british columbia
90. Present evidence on the value of HPV testing for cervical cancer screening
91. The costs and effectiveness of cervical cancer screening in the elderly
92. Test reliability is critically important to molecular epidemiology
93. Accuracy and interlaboratory reliability of human papillomavirus DNA testing by hybrid capture
94. Human papillomavirus (HPV) in an icelandic population: The role of HPV DNA testing based on hybrid capture and PCR assays among women with screen-detected abnormal Pap smears
95. Human papillomavirus testing for primary screening of cervical cancer precursors
96. Breast and cervical cancer screening for older women: Recommendations and challenges for the 21st century
97. Gynecological care of elderly women
98. Prevalence and histologic significance of cervical human papillomavirus DNA detected in women at low and high risk for cervical neoplasia
99. Combining independent studies of a diagnostic test into a summary ROC curve
100. Hybrid capture method for detection of human papillomavirus DNA in clinical specimens
101. Molecular methods for the detection of human papillomavirus infection
102. Results of outpatient therapy of cervical intraepithelial neoplasia
103. Cervical intraepithelial neoplasia (dysplasia and carcinoma in situ) and early invasive cervical carcinoma
104. Costs and benefits of cervical screening, I: The costs of the cervical screening programme
105. The management of cervical intraepithelial neoplasia (CIN)
106. Estimating costs in cost-effectiveness analysis
107. The benefits and costs of alternative strategies to screen for cervical cancer in less-developed countries
108. Uncertainty in decision modeling analyzing cost-effectiveness
109. Setting the target for a better cervical screening test
110. HPV cervical neoplasia
111. Can papilloma virus testing be used to improve cervical cancer screening?
112. A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme
113. Use of a Hybrid capture assay of self-collected vaginal swabs in rural Uganda for detection of human papillomavirus
114. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings
115. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions
116. Socioeconomic factors and cancer incidence among blacks and whites
117. Change in American Cancer Society check-up guidelines for detection of cervical cancer
118. Advancing age and cervical cancer screening and prognosis
119. The positive predictive value of cervical smears in previously screened post-menopausal women: The Heart and Estrogen/progestin Replacement Study (HERS)
120. The frequency of cervical cancer screening: Comparison of a mathematical model with empirical data
121. Guidelines for management of abnormal cervical cytology
122. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance
123. Cervical-cancer screening: Attendence and cost-effectiveness